CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for HemaCare Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

HemaCare Corporation
15350 Sherman Way
Suite 423
Phone: (877) 310-0717p:877 310-0717 Van Nuys, CA  91406-4203  United States Fax: (818) 251-5300f:818 251-5300
This company was Merged or Acquired on 1/3/2020.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
HemaCare Corporation is a blood products and services company. The Company provides healthy and disease state human-derived primary blood cells and tissues derived from normal and mobilized peripheral blood, bone marrow and cord blood for biomedical research, supports cell therapy clinical trials and commercialization with apheresis collections, and provides a range of consulting services in standard operating procedure (SOP) development, personnel training, and quality and regulatory compliance. Its products include CryoStor CS10, CryoStor CS5, Mobilized PB Leukopak, Monouclear Cells and CD133+ Stem/Progenitor Cells, among others. It supports industry and academic organizations with apheresis collection services for preclinical research, clinical trials from Phase I through Phase III, and clinical cell therapy applications. It specializes in customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201912/31/2018YesYes---

Industries
SIC Code Description
8099 Health and allied services, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Steven B.Gerber 58 5/27/2009 10/1/2003
President, Chief Executive Officer,Director Peter C.Van der Wal 55 3/9/2011 2/27/2010
Chief Financial Officer Lisa B.Bacerra 55 8/1/2010 8/1/2010
4 additional Officers and Directors records available in full report.

Business Names
Business Name
HEMA
HemaBiologics, Inc.
HemaCare BioScience, Inc.

General Information
Number of Employees: 85 (As of 12/31/2011)
Outstanding Shares: 13,657,206 (As of 6/30/2019)
Shareholders: 249
Stock Exchange: OTC
Federal Tax Id: 953280412
Fax Number: (818) 251-5300
Email Address: investor@hemacare.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, August 4, 2023